Intersect Ent, Inc. (XENT): James Stambaugh , VP Clinical Affairs of Intersect Ent, Inc. sold 500 shares on Jun 13, 2016. The Insider selling transaction was reported by the company on Jun 14, 2016 to the Securities and Exchange Commission. The shares were sold at $14.38 per share for a total value of $7,191.05 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 28, 2016, Amy Wolbeck (V.P. Regulatory Affairs & Qlty) sold 2,000 shares at $20.01 per share price.On Apr 22, 2016, Richard E Kaufman (Sr VP& Chief Operating Officer) sold 3,603 shares at $18.85 per share price.Also, On Apr 19, 2016, Lisa D Earnhardt (President and CEO) sold 28,500 shares at $18.92 per share price.On Jul 21, 2015, James Stambaugh (VP Clinical Affairs) sold 12,000 shares at $30.52 per share price.
Shares of Intersect ENT Inc (XENT) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -0.29 points or -1.97% at $14.4 with 1,99,029 shares getting traded. Post opening the session at $14.45, the shares hit an intraday low of $14.21 and an intraday high of $14.73 and the price vacillated in this range throughout the day. The company has a market cap of $408 M and the number of outstanding shares has been calculated to be 2,83,26,471 shares. The 52-week high of Intersect ENT Inc is $32.85 and the 52-week low is $11.977.
Intersect ENT Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear nose and throat conditions. The Company’s commercial products are the PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is also developing PROPEL mini for use in frontal sinus surgery and is conducting clinical trials to evaluate two products RESOLVE and NOVA for treatment of patients in the physician’s office. The Company is developing the RESOLVE steroid releasing implant as an alternative treatment option for patients who are candidates for revision surgery that can be placed in the physician office setting during a routine visit. The Company is also developing NOVA a steroid releasing implant designed to fit the openings of the frontal and maxillary sinuses following ostial dilation using balloon sinuplasty.